PFE - BioNTech Prepares To Be Commercial Ready By 2025 Revenue Growth Expected To Return In 2025 | Benzinga
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P. Morgan Healthcare Conference and said it expects to grow its topline again in 2025.
In the outer years, the company projects revenues from oncology and respiratory combination vaccine launches, subject to successful development and regulatory approval.
Pfizer Inc's (NYSE: PFE) partner for COVID shots forecasts FY24 total revenue of €3 billion, down from Full story available on Benzinga.com